4D Molecular Therapeutics, Inc. (FDMT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 14 | 18 | 3 | 21 | 0 | 85 | 92 | - |
| Operating profit | $m | -160 | -197 | ||||||
| Net profit | $m | -57 | -71 | -107 | -101 | -161 | -140 | -179 | -238 |
| EPS reported | $ | -2.42 | -2.72 | ||||||
| Operating cashflow per share | $ | -1.88 | -2.22 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -1.88 | -2.23 | ||||||
| Free cash flow | $m | -109 | -157 | ||||||
| Net debt | $m | -403 | -342 | ||||||
| Book value equity | $m | 506 | 408 | ||||||
| Book value per share | $ | 8.73 | 5.80 | ||||||
| Number of shares | m | 57.93 | 70.27 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.86 | 1.07 | ||||||
| P/S LTM | x | 5.10 | 4.72 | ||||||
| P/FCF LTM | x | -3.98 | -2.77 | ||||||
| EV/EBITDA LTM | x | -2.99 | -2.14 | ||||||
| EV/Sales LTM | x | 4.64 | 6.37 | ||||||
| Earnings Yield LTM | % | -32.25% | -20.92% | ||||||
| FCF Yield | % | -25.11% | -36.06% | ||||||
| Quality | |||||||||
| ROE | % | -27.71% | -41.33% | ||||||
| ROIC | % | -30.20% | -43.77% | ||||||
| Operating margin | % | -1.87% | -2.14% | ||||||
| Gross margin | % | +91.05% | +44.27% | ||||||
| FCF/Sales | % | -128.02% | -170.27% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -5.09 | -3.99 | ||||||
| Net Debt/EBITDA | x | 0.29 | 0.27 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +3.08% | ||||||
| Net debt/Equity | x | -0.80 | -0.84 | ||||||
| Gross debt/equity | x | 0.04 | 0.10 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
4D Molecular Therapeutics, Inc. (FDMT)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free